alnylam
The Senior Director, Toxicology provides strategic scientific leadership for nonclinical safety across multiple research and development programs. This role shapes nonclinical development strategy and provides scientific oversight for the design, conduct, and reporting of GLP and non-GLP toxicology studies. The position partners with cross-functional teams to evaluate complex scientific and regulatory issues, informing program and portfolio decisions from discovery through registration.
Headquarters
Cambridge, Massachusetts, United States
Company Size
1001-5000 employees
Founded
2002
Alnylam is a biopharmaceutical company that has pioneered RNA interference (RNAi) therapeutics, an innovative class of medicines that treats diseases by silencing the genes that cause or contribute to them. The company develops RNAi-based medicines targeting both rare and prevalent diseases across multiple therapeutic areas, with approved products and a robust investigational pipeline. Driven by science and inspired by patients, Alnylam is committed to delivering transformational medicines that address diseases at their genetic source.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for alnylam.
14% above the average for this role
Director, Toxicology
Praxis Precision Medicines, Inc.
Senior Director, Toxicology
Disc Medicine
Director, Toxicology Translational Science
Tarsus Pharmaceuticals
Senior Toxicologist - Study Monitor
Eli Lilly and Company
Director of Nonclinical Development, Toxicology
Rhythm Pharmaceuticals
Associate Director, Toxicology, Nonclinical Development (Program Toxicologist)
8a7882525b6027b0015b692822e001ab